CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
personal-finance
4 income investing mistakes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,079.20 | 17.70 | 0.20% |
CAC 40 | 7,870.68 | 75.26 | 0.97% |
DAX 40 | 23,739.47 | 204.64 | 0.87% |
Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
FTSE 100 | 9,284.83 | 70.85 | 0.77% |
HKSE | 26,128.20 | 356.48 | -1.35% |
NASDAQ | 22,484.07 | 99.37 | 0.44% |
Nikkei 225 | 45,354.99 | 399.94 | -0.87% |
NZX 50 Index | 13,111.73 | 42.06 | -0.32% |
S&P 500 | 6,643.70 | 38.98 | 0.59% |
S&P/ASX 200 | 8,787.70 | 13.20 | 0.15% |
SSE Composite Index | 3,828.11 | 25.20 | -0.65% |